Quince Therapeutics (QNCX) News Today $1.84 +0.07 (+3.95%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Quince Therapeutics Share Price (QNCX.US)November 18 at 7:14 PM | lse.co.ukShort Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Increases By 23.0%Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,350,000 shares, an increase of 23.0% from the October 15th total of 1,910,000 shares. Based on an average trading volume of 554,300 shares, the days-to-cover ratio is presently 4.2 days. Approximately 7.3% of the company's stock are sold short.November 15, 2024 | marketbeat.comQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comQuince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchNovember 13, 2024 | finance.yahoo.comQuince Therapeutics presents safety data from ATTeST trial at CNS meetingNovember 13, 2024 | markets.businessinsider.comQuince Therapeutics presents data from prior Phase 3 ATTeST clinical trialNovember 13, 2024 | markets.businessinsider.comQuince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingNovember 11, 2024 | businesswire.comQuince Therapeutics initiated with a Buy at MaximNovember 8, 2024 | markets.businessinsider.comMaxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationNovember 8, 2024 | msn.comMaxim Group Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)Maxim Group initiated coverage on shares of Quince Therapeutics in a research report on Thursday. They issued a "buy" rating and a $6.00 price objective for the company.November 7, 2024 | marketbeat.comQuince Therapeutics initiated with a Buy at Rodman & RenshawOctober 30, 2024 | markets.businessinsider.comQuince Therapeutics (NASDAQ:QNCX) Upgraded at RODMAN&RENSHAWRODMAN&RENSHAW raised shares of Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday.October 30, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationOctober 30, 2024 | msn.comEF Hutton Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationOctober 22, 2024 | msn.comQuince Therapeutics to Participate at Upcoming Investor ConferencesOctober 14, 2024 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 SharesSeptember 4, 2024 | insidertrades.comQuince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comQNCX Quince Therapeutics, Inc.August 30, 2024 | seekingalpha.comQuince Therapeutics, Inc. (NASDAQ:QNCX) President Charles S. Ryan Acquires 48,387 SharesAugust 23, 2024 | insidertrades.comQuince Therapeutics, Inc. (NASDAQ:QNCX) COO Brendan Hannah Acquires 30,845 SharesAugust 22, 2024 | insidertrades.comQuince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDexAugust 20, 2024 | seekingalpha.comQuince reports data from Phase III Ataxia-Telangiectasia treatment trialAugust 17, 2024 | finance.yahoo.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024August 13, 2024 | investorplace.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | stockhouse.comQuince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-TelangiectasiaJune 25, 2024 | businesswire.comQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemJune 3, 2024 | businesswire.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024May 13, 2024 | investorplace.comQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | businesswire.comQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceMay 6, 2024 | businesswire.comQuince Therapeutics, Inc. (QNCX)April 25, 2024 | finance.yahoo.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023April 2, 2024 | investorplace.comQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsApril 1, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | businesswire.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | finance.yahoo.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Drop in Short InterestQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,900,000 shares, a decrease of 7.3% from the January 15th total of 2,050,000 shares. Currently, 6.0% of the company's shares are sold short. Based on an average trading volume of 91,100 shares, the days-to-cover ratio is presently 20.9 days.February 15, 2024 | marketbeat.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | businesswire.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%Quince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%February 14, 2024 | marketbeat.comQuince Therapeutics to Participate at Investor Events in January 2024January 4, 2024 | finance.yahoo.comQuince Therapeutics Inc QNCXNovember 11, 2023 | morningstar.comChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 SharesOctober 27, 2023 | benzinga.comQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock OptionsOctober 25, 2023 | benzinga.comQuince Therapeutics Completes Acquisition of EryDel S.p.A.October 23, 2023 | finance.yahoo.comFDA lifts partial clinical hold on EryDel lead product EryDexSeptember 28, 2023 | msn.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 28, 2023 | finance.yahoo.comQuince Therapeutics President Awarded $692K Worth of Stock OptionsSeptember 7, 2023 | benzinga.comDaily Digest: Currys aim to raise $50M for Oakland schools; Sotheby's opens new officeSeptember 6, 2023 | bizjournals.comQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentSeptember 6, 2023 | finance.yahoo.com325K Reasons To Be Bullish On Quince Therapeutics StockAugust 18, 2023 | benzinga.comQuince Therapeutics And 2 Other Stocks Under $3 Insiders Are BuyingAugust 14, 2023 | benzinga.com Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide QNCX Media Mentions By Week QNCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼0.920.45▲Average Medical News Sentiment QNCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼30▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Generation Bio News Coherus BioSciences News Atara Biotherapeutics News Compugen News Adverum Biotechnologies News AC Immune News COMPASS Pathways News Jasper Therapeutics News Design Therapeutics News Lyell Immunopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
